{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T19:43:49Z","timestamp":1785527029118,"version":"3.56.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The Hebei Provincial Natural Science Foundation, the Jing-Jin-Ji Special Projects for Basic Research Cooperation","award":["H2018206600"],"award-info":[{"award-number":["H2018206600"]}]},{"name":"The Hengrui Hebei Collaborative Innovation Program in Medical Science","award":["HR202502074"],"award-info":[{"award-number":["HR202502074"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s00259-026-07920-4","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T01:29:45Z","timestamp":1780018185000},"page":"5950-5962","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of [68Ga]Ga-HER2 Affibody PET\/CT and MRI for the early prediction of response to targeted neoadjuvant therapy in breast cancer"],"prefix":"10.1007","volume":"53","author":[{"given":"Ran","family":"An","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruoxi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoshan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Pang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianqiang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangyu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingya","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7060-2643","authenticated-orcid":false,"given":"Xinming","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"7920_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"key":"7920_CR2","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1056\/NEJMcibr1909386","volume":"381","author":"DF Hayes","year":"2019","unstructured":"Hayes DF. HER2 and Breast Cancer - A Phenomenal Success Story. N Engl J Med. 2019;381:1284\u20136. https:\/\/doi.org\/10.1056\/NEJMcibr1909386.","journal-title":"N Engl J Med"},{"key":"7920_CR3","doi-asserted-by":"publisher","unstructured":"Hrynchak I, Santos L, Falc\u00e3o A, Gomes CM, Abrunhosa AJ. Nanobody-based theranostic agents for HER2-Positive breast cancer: radiolabeling strategies. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms221910745.","DOI":"10.3390\/ijms221910745"},{"key":"7920_CR4","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.2147\/dddt.S253961","volume":"14","author":"H Wang","year":"2020","unstructured":"Wang H, Mao X. Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer. Drug Des Devel Ther. 2020;14:2423\u201333. https:\/\/doi.org\/10.2147\/dddt.S253961.","journal-title":"Drug Des Devel Ther"},{"key":"7920_CR5","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.2967\/jnumed.123.266079","volume":"64","author":"L Chen","year":"2023","unstructured":"Chen L, Zheng S, Chen L, Xu S, Wu K, Kong L, et al. (68)Ga-Labeled Fibroblast Activation Protein Inhibitor PET\/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study. J Nucl Med. 2023;64:1899\u2013905. https:\/\/doi.org\/10.2967\/jnumed.123.266079.","journal-title":"J Nucl Med"},{"key":"7920_CR6","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1007\/s00259-014-2770-2","volume":"41","author":"KE Pengel","year":"2014","unstructured":"Pengel KE, Koolen BB, Loo CE, Vogel WV, Wesseling J, Lips EH, et al. Combined use of \u00b9\u2078F-FDG PET\/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41:1515\u201324. https:\/\/doi.org\/10.1007\/s00259-014-2770-2.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7920_CR7","doi-asserted-by":"publisher","first-page":"7994","DOI":"10.1007\/s00330-024-10857-7","volume":"34","author":"A van der Voort","year":"2024","unstructured":"van der Voort A, van der Hoogt KJJ, Wessels R, Schipper RJ, Wesseling J, Sonke GS, et al. Diffusion-weighted imaging in addition to contrast-enhanced MRI in identifying complete response in HER2-positive breast cancer. Eur Radiol. 2024;34:7994\u20138004. https:\/\/doi.org\/10.1007\/s00330-024-10857-7.","journal-title":"Eur Radiol"},{"key":"7920_CR8","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.2967\/jnumed.122.265364","volume":"64","author":"A Alhuseinalkhudhur","year":"2023","unstructured":"Alhuseinalkhudhur A, Lindman H, Liss P, Sundin T, Frejd FY, Hartman J, et al. Human Epidermal Growth Factor Receptor 2-Targeting [(68)Ga]Ga-ABY-025 PET\/CT Predicts Early Metabolic Response in Metastatic Breast Cancer. J Nucl Med. 2023;64:1364\u201370. https:\/\/doi.org\/10.2967\/jnumed.122.265364.","journal-title":"J Nucl Med"},{"key":"7920_CR9","doi-asserted-by":"publisher","first-page":"e232209","DOI":"10.1148\/radiol.232209","volume":"311","author":"X Guo","year":"2024","unstructured":"Guo X, Zhou N, Liu J, Ding J, Liu T, Song G, et al. Comparison of an Affibody-based Molecular Probe and (18)F-FDG for Detecting HER2-Positive Breast Cancer at PET\/CT. Radiology. 2024;311:e232209. https:\/\/doi.org\/10.1148\/radiol.232209.","journal-title":"Radiology"},{"key":"7920_CR10","doi-asserted-by":"publisher","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","volume":"22","author":"WJ Gradishar","year":"2024","unstructured":"Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024;22:331\u201357. https:\/\/doi.org\/10.6004\/jnccn.2024.0035.","journal-title":"J Natl Compr Canc Netw"},{"key":"7920_CR11","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1007\/s00259-011-1810-4","volume":"38","author":"G Kramer-Marek","year":"2011","unstructured":"Kramer-Marek G, Shenoy N, Seidel J, Griffiths GL, Choyke P, Capala J. 68Ga-DOTA-affibody molecule for in vivo assessment of HER2\/neu expression with PET. Eur J Nucl Med Mol Imaging. 2011;38:1967\u201376. https:\/\/doi.org\/10.1007\/s00259-011-1810-4.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7920_CR12","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026.","journal-title":"Eur J Cancer"},{"key":"7920_CR13","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1200\/jco.23.00435","volume":"41","author":"JK Litton","year":"2023","unstructured":"Litton JK, Regan MM, Pusztai L, Rugo HS, Tolaney SM, Garrett-Mayer E, et al. Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP. J Clin Oncol. 2023;41:4433\u201342. https:\/\/doi.org\/10.1200\/jco.23.00435.","journal-title":"J Clin Oncol"},{"key":"7920_CR14","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1200\/jco.2007.10.6823","volume":"25","author":"WF Symmans","year":"2007","unstructured":"Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414\u201322. https:\/\/doi.org\/10.1200\/jco.2007.10.6823.","journal-title":"J Clin Oncol"},{"key":"7920_CR15","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2967\/jnumed.123.266392","volume":"65","author":"R Yeh","year":"2024","unstructured":"Yeh R, O\u2019Donoghue JA, Jayaprakasam VS, Mauguen A, Min R, Park S, et al. First-in-Human Evaluation of Site-Specifically Labeled (89)Zr-Pertuzumab in Patients with HER2-Positive Breast Cancer. J Nucl Med. 2024;65:386\u201393. https:\/\/doi.org\/10.2967\/jnumed.123.266392.","journal-title":"J Nucl Med"},{"key":"7920_CR16","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.breast.2020.06.001","volume":"53","author":"A Surov","year":"2020","unstructured":"Surov A, Wienke A, Meyer HJ. Pretreatment apparent diffusion coefficient does not predict therapy response to neoadjuvant chemotherapy in breast cancer. Breast. 2020;53:59\u201367. https:\/\/doi.org\/10.1016\/j.breast.2020.06.001.","journal-title":"Breast"},{"key":"7920_CR17","doi-asserted-by":"publisher","first-page":"111656","DOI":"10.1016\/j.ejrad.2024.111656","volume":"178","author":"S Chen","year":"2024","unstructured":"Chen S, Zheng B, Tang W, Ding S, Sui Y, Yu X, et al. The longitudinal changes in multiparametric MRI during neoadjuvant chemotherapy can predict treatment response early in patients with HER2-positive breast cancer. Eur J Radiol. 2024;178:111656. https:\/\/doi.org\/10.1016\/j.ejrad.2024.111656.","journal-title":"Eur J Radiol"},{"key":"7920_CR18","doi-asserted-by":"publisher","first-page":"1544058","DOI":"10.3389\/fonc.2025.1544058","volume":"15","author":"L Wang","year":"2025","unstructured":"Wang L, Yang J, Yang L, Zhu Y, Tang X, Cao X, et al. Developing a predictive model for neoadjuvant therapy in HER2 overexpression breast cancer using multi-parameter MRI radiomics: two-center retrospective study. Front Oncol. 2025;15:1544058. https:\/\/doi.org\/10.3389\/fonc.2025.1544058.","journal-title":"Front Oncol"},{"key":"7920_CR19","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s00259-025-07444-3","volume":"53","author":"S Zheng","year":"2025","unstructured":"Zheng S, Xu F, Chen Y, Shao Z, Wu Z, Liu Q, et al. The value of serial [68Ga]Ga-FAPI-04 PET\/CT in predicting pathological response and evaluating therapeutic efficacy to neoadjuvant chemotherapy in breast cancer. Eur J Nucl Med Mol Imaging. 2025;53:362\u201373. https:\/\/doi.org\/10.1007\/s00259-025-07444-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7920_CR20","doi-asserted-by":"publisher","first-page":"100935","DOI":"10.1016\/j.modpat.2025.100935","volume":"39","author":"J Hu","year":"2026","unstructured":"Hu J, Tsang JY, Liu J, Hu H, Guo D, Tse GM. Predictors of Response to Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Pathological Evaluation of HER2 Heterogeneity. Mod Pathol. 2026;39:100935. https:\/\/doi.org\/10.1016\/j.modpat.2025.100935.","journal-title":"Mod Pathol"},{"key":"7920_CR21","doi-asserted-by":"publisher","first-page":"3709","DOI":"10.1007\/s00259-024-06815-6","volume":"51","author":"C Oliveira","year":"2024","unstructured":"Oliveira C, Oliveira F, Constantino C, Alves C, Brito MJ, Cardoso F, et al. Baseline [(18)F]FDG PET\/CT and MRI first-order breast tumor features do not improve pathological complete response prediction to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2024;51:3709\u201318. https:\/\/doi.org\/10.1007\/s00259-024-06815-6.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7920_CR22","doi-asserted-by":"publisher","first-page":"105875","DOI":"10.1016\/j.esmoop.2025.105875","volume":"10","author":"JJ Garc\u00eda-Mosquera","year":"2025","unstructured":"Garc\u00eda-Mosquera JJ, P\u00e9rez-Garc\u00eda JM, Ruiz-Borrego M, Stradella A, Bermejo B, Escriv\u00e1-de-Roman\u00ed S, et al. Comparing [(18)F]FDG-positron emission tomography and breast magnetic resonance imaging to predict pathological complete response and 3-year invasive disease-free survival in HER2-positive early breast cancer patients: an unplanned exploratory analysis of the PHERGain trial. ESMO Open. 2025;10:105875. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105875.","journal-title":"ESMO Open"},{"key":"7920_CR23","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.2967\/jnumed.112.119271","volume":"54","author":"G Gebhart","year":"2013","unstructured":"Gebhart G, G\u00e1mez C, Holmes E, Robles J, Garcia C, Cort\u00e9s M, et al. 18F-FDG PET\/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO. J Nucl Med. 2013;54:1862\u20138. https:\/\/doi.org\/10.2967\/jnumed.112.119271.","journal-title":"J Nucl Med"},{"key":"7920_CR24","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1158\/1078-0432.Ccr-13-2421","volume":"20","author":"S Trousil","year":"2014","unstructured":"Trousil S, Hoppmann S, Nguyen QD, Kaliszczak M, Tomasi G, Iveson P, et al. Positron emission tomography imaging with 18F-labeled ZHER2:2891 affibody for detection of HER2 expression and pharmacodynamic response to HER2-modulating therapies. Clin Cancer Res. 2014;20:1632\u201343. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-13-2421.","journal-title":"Clin Cancer Res"},{"key":"7920_CR25","doi-asserted-by":"publisher","first-page":"102635","DOI":"10.1016\/j.mtbio.2025.102635","volume":"35","author":"X Xue","year":"2025","unstructured":"Xue X, Li X, Tian M, Yu L, Qian J, Bai X, et al. PH20-modified exosomes loaded curcumin inhibit desmoplastic breast cancer by breaking extracellular matrix barrier and normalizing cancer-associated fibroblasts. Mater Today Bio. 2025;35:102635. https:\/\/doi.org\/10.1016\/j.mtbio.2025.102635.","journal-title":"Mater Today Bio"},{"key":"7920_CR26","doi-asserted-by":"publisher","first-page":"4525","DOI":"10.1007\/s00259-025-07220-3","volume":"52","author":"Y Gao","year":"2025","unstructured":"Gao Y, Yin L, Duan X, Fu Z, Liu Q, Chen J, et al. HER2-targeted PET\/CT imaging provides potential biomarkers for differentiating HER2-zero, -low, and -positive breast cancer. Eur J Nucl Med Mol Imaging. 2025;52:4525\u201338. https:\/\/doi.org\/10.1007\/s00259-025-07220-3.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"7920_CR27","doi-asserted-by":"publisher","first-page":"12631","DOI":"10.21037\/qims-2025-1167","volume":"15","author":"A Ren","year":"2025","unstructured":"Ren A, Liu J, Li Y, Tang Z, Li Y, Wang R, et al. Percentage apparent diffusion coefficient change for early prediction of response to neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis, and a retrospective study. Quant Imaging Med Surg. 2025;15:12631\u201344. https:\/\/doi.org\/10.21037\/qims-2025-1167.","journal-title":"Quant Imaging Med Surg"},{"key":"7920_CR28","doi-asserted-by":"publisher","first-page":"W1","DOI":"10.7326\/m14-0698","volume":"162","author":"KG Moons","year":"2015","unstructured":"Moons KG, Altman DG, Reitsma JB, Ioannidis JP, Macaskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162:W1\u201373. https:\/\/doi.org\/10.7326\/m14-0698.","journal-title":"Ann Intern Med"},{"key":"7920_CR29","doi-asserted-by":"publisher","first-page":"16372","DOI":"10.1038\/s41598-019-52785-3","volume":"9","author":"NP Pereira","year":"2019","unstructured":"Pereira NP, Curi C, Os\u00f3rio C, Marques EF, Makdissi FB, Pinker K, et al. Diffusion-Weighted Magnetic Resonance Imaging of Patients with Breast Cancer Following Neoadjuvant Chemotherapy Provides Early Prediction of Pathological Response - A Prospective Study. Sci Rep. 2019;9:16372. https:\/\/doi.org\/10.1038\/s41598-019-52785-3.","journal-title":"Sci Rep"},{"key":"7920_CR30","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1148\/radiol.2017161548","volume":"286","author":"I Fukada","year":"2018","unstructured":"Fukada I, Araki K, Kobayashi K, Shibayama T, Takahashi S, Gomi N, et al. Pattern of Tumor Shrinkage during Neoadjuvant Chemotherapy Is Associated with Prognosis in Low-Grade Luminal Early Breast Cancer. Radiology. 2018;286:49\u201357. https:\/\/doi.org\/10.1148\/radiol.2017161548.","journal-title":"Radiology"},{"key":"7920_CR31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40644-025-00971-0","volume":"26","author":"J Wang","year":"2025","unstructured":"Wang J, Liu Y, Liu T, Li Y, Ma X, Zhao Y, et al. Tumor shrinkage patterns and optimal timing of response assessment during neoadjuvant therapy for breast cancer: a study based on multiparametric MRI. Cancer Imaging. 2025;26:2. https:\/\/doi.org\/10.1186\/s40644-025-00971-0.","journal-title":"Cancer Imaging"},{"key":"7920_CR32","doi-asserted-by":"publisher","first-page":"101899","DOI":"10.1016\/j.eclinm.2023.101899","volume":"58","author":"Y Huang","year":"2023","unstructured":"Huang Y, Zhu T, Zhang X, Li W, Zheng X, Cheng M, et al. Longitudinal MRI-based fusion novel model predicts pathological complete response in breast cancer treated with neoadjuvant chemotherapy: a multicenter, retrospective study. EClinicalMedicine. 2023;58:101899. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101899.","journal-title":"EClinicalMedicine"},{"key":"7920_CR33","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1007\/s12282-013-0449-3","volume":"21","author":"H Fujimoto","year":"2014","unstructured":"Fujimoto H, Kazama T, Nagashima T, Sakakibara M, Suzuki TH, Okubo Y, et al. Diffusion-weighted imaging reflects pathological therapeutic response and relapse in breast cancer. Breast Cancer. 2014;21:724\u201331. https:\/\/doi.org\/10.1007\/s12282-013-0449-3.","journal-title":"Breast Cancer"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07920-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-026-07920-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-026-07920-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T18:08:03Z","timestamp":1785521283000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-026-07920-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":33,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["7920"],"URL":"https:\/\/doi.org\/10.1007\/s00259-026-07920-4","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"1 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Institutional Review Board approval was obtained (Institutional Ethics Committee of the Fourth Hospital of Hebei Medical University).","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consents were obtained from the included subjects for participation in this study.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors affirm that all human participants in volved in this study have signed the consent form and agreed to the publication of their medical imaging.","order":3,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors of this manuscript declare no relationships with any companies whose products.","order":4,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}